ZVSA
ZyVersa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.10
−0.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 6.9K | 10.4K | 10.4K |
| Gross Profit | — | — | (6.9K) | (10.4K) | (10.4K) |
| Operating Expenses | |||||
| R&D Expense | 911.9M | 1.1B | 1.8B | 3.2M | 5.4M |
| SG&A Expense | 5.1B | 5.7B | 7.4B | 11.2M | 7.6M |
| General & Admin Expense | 5.1B | 5.7B | 7.4B | 11.2B | 7.6M |
| Selling & Marketing Expense | — | — | — | (11.2B) | — |
| Other Expenses | (6.0B) | (6.8B) | (9.1B) | — | 809.7K |
| Total Operating Expenses | 6.0M | 6.8M | 9.1M | 14.4M | 13.8M |
| Cost and Expenses | 6.0M | 6.8M | 9.1M | 14.4M | 13.8M |
| Operating Income (EBIT) | 2.1B | (6.8M) | (9.1B) | (14.4M) | (13.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 457.00 | 427.54 |
| Interest Expense | 526.2K | 513.2K | 269.9K | — | 427.5K |
| Net Interest Income | (526.2K) | (513.2K) | (269.9K) | 457.00 | (427.1K) |
| Other Non-Op Income/Expense | 92.9M | (19.0M) | (283.3M) | (93.3M) | (1.0M) |
| Non-Operating Income (excl Interest) | 393.3K | — | — | 93.3M | 607.0K |
| EBT (Pre-Tax Income) | 2.2B | (25.8M) | (9.4B) | (107.8M) | (14.9M) |
| Income Tax Expense | (851.7K) | (851.7K) | (6.7M) | (9.5M) | (745.0K) |
| Bottom Line | |||||
| Net Income | (24.5M) | (25.0M) | (9.4B) | (98.3M) | (14.0M) |
| Earnings from Cont. Ops | (24.5M) | (25.0M) | (9.4B) | (98.3M) | (14.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.5M) | (25.0M) | (9.4B) | (106.2M) | (24.1M) |
| Per Share | |||||
| Basic EPS | ($3.32) | ($4.18) | ($8.48) | ($1,089.66) | ($930.25) |
| Diluted EPS | ($3.32) | ($4.18) | ($8.48) | ($1,089.66) | ($930.25) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 8.1B | 6.0B | 1.1M | 97503 | 25948 |
| Diluted Shares Outstanding | 8.1B | 6.0B | 1.1M | 97503 | 25948 |
| Profitability Metrics | |||||
| EBITDA | (24.7M) | (25.3M) | (9.1B) | (107.7M) | (14.4M) |
| D&A | — | — | 6.9K | 10.4K | 10.4K |
| EBIT | (24.7M) | (25.3M) | (9.2B) | (107.8M) | (14.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026